BRPI0509753A - composição farmacêutica e método de tratamento de doença cardiovascular - Google Patents
composição farmacêutica e método de tratamento de doença cardiovascularInfo
- Publication number
- BRPI0509753A BRPI0509753A BRPI0509753-3A BRPI0509753A BRPI0509753A BR PI0509753 A BRPI0509753 A BR PI0509753A BR PI0509753 A BRPI0509753 A BR PI0509753A BR PI0509753 A BRPI0509753 A BR PI0509753A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- cardiovascular disease
- treating cardiovascular
- patient
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composição farmacêutica e método de tratamento de doença cardiovascular. São reveladas composições farmacêuticas que compreendem um inibidor de aldosterona e um antagonista de receptor A1 da adenosina (AA1RA) e métodos de tratamento de doença cardiovascular que compreendem identificar um paciente carecido desse tratamento e administrar uma composição farmacêutica aqui revelada ao referido paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56316604P | 2004-04-16 | 2004-04-16 | |
PCT/US2005/012724 WO2005105083A1 (en) | 2004-04-16 | 2005-04-14 | Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0509753A true BRPI0509753A (pt) | 2007-10-16 |
Family
ID=34965807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0509753-3A BRPI0509753A (pt) | 2004-04-16 | 2005-04-14 | composição farmacêutica e método de tratamento de doença cardiovascular |
Country Status (10)
Country | Link |
---|---|
US (2) | US20050239759A1 (pt) |
EP (1) | EP1755594A1 (pt) |
JP (1) | JP2007532671A (pt) |
KR (1) | KR20070008689A (pt) |
CN (1) | CN101094671A (pt) |
AU (1) | AU2005237466A1 (pt) |
BR (1) | BRPI0509753A (pt) |
CA (1) | CA2568436A1 (pt) |
MX (1) | MXPA06011823A (pt) |
WO (1) | WO2005105083A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006524699A (ja) * | 2003-04-25 | 2006-11-02 | ノヴァカーディア,インク. | 腎機能障害を持つ個体における利尿改善法 |
US20060293312A1 (en) * | 2003-04-25 | 2006-12-28 | Howard Dittrich | Method of improved diuresis in individuals with impaired renal function |
KR20080110776A (ko) * | 2006-04-06 | 2008-12-19 | 노바카르디아, 인코포레이션 | 아데노신 a₁ 수용체 길항제 및 항경련제의 공동 투여 |
WO2007149366A1 (en) * | 2006-06-16 | 2007-12-27 | Novacardia, Inc. | Prolonged improvement of renal function comprising infrequent administration of an aa1ra |
JP2010501557A (ja) * | 2006-08-22 | 2010-01-21 | ノヴァカーディア,インク. | 血液脳関門を通過しないkw−3902コンジュゲート |
WO2008121882A1 (en) * | 2007-03-29 | 2008-10-09 | Novacardia, Inc. | Improved methods of administration of adenosine a1 receptor antagonists |
US20090197900A1 (en) * | 2007-03-29 | 2009-08-06 | Howard Dittrich | Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist |
WO2018153898A1 (de) * | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE416810C (sv) * | 1977-10-14 | 1982-07-19 | Draco Ab | Forfarande for framstellning av xantinderivat med antiallergisk aktivitet |
FR2531085A1 (fr) * | 1982-07-28 | 1984-02-03 | Adir | Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant |
DE8817122U1 (de) * | 1988-12-22 | 1993-02-04 | Boehringer Ingelheim Kg, 55218 Ingelheim | Neue Xanthinderivate mit Adenosinantogenistischer Wirkung |
US5290782A (en) * | 1989-09-01 | 1994-03-01 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
DE4238367A1 (de) * | 1992-11-13 | 1994-05-19 | Boehringer Ingelheim Kg | Diuretisches Mittel |
US5395836A (en) * | 1993-04-07 | 1995-03-07 | Kyowa Hakko Kogyo Co., Ltd. | 8-tricycloalkyl xanthine derivatives |
US5446046A (en) * | 1993-10-28 | 1995-08-29 | University Of Florida Research Foundation | A1 adenosine receptor agonists and antagonists as diuretics |
US5736528A (en) * | 1993-10-28 | 1998-04-07 | University Of Florida Research Foundation, Inc. | N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists |
US6254889B1 (en) * | 1995-07-26 | 2001-07-03 | Kyowa Hakko Kogyo Co., Ltd. | Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer |
CN1227490A (zh) * | 1996-08-07 | 1999-09-01 | 协和发酵工业株式会社 | 含有黄嘌呤衍生物的脂肪乳剂 |
US6117445A (en) * | 1998-01-28 | 2000-09-12 | Link Technology Inc. | Methods for the prevention and treatment of fibrosis and sclerosis |
US6187780B1 (en) * | 1998-04-16 | 2001-02-13 | Boehringer Ingelheim Pharma Kg | Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity |
US20020115687A1 (en) * | 1998-04-24 | 2002-08-22 | Evan Beckman | Method and composition for restoring diuretic and renal function |
ES2211079T3 (es) * | 1998-04-24 | 2004-07-01 | Cv Therapeutics | Composicion que contiene un antagonista del receptor a1 de adenosina y metodo para restablecer la funcion diuretica y renal. |
EP0970696A1 (en) * | 1998-05-05 | 2000-01-12 | Kyowa Hakko Kogyo Co., Ltd. | Combination of loop diuretics with adenosine A1-receptor antagonists |
UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
US20050250748A1 (en) * | 1999-03-05 | 2005-11-10 | G. D. Searle & Co. | Combination therapy of angiotensin converting enzyme inhibitor and eplerenone for treatment of cardiovascular disease |
US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
JP2006524699A (ja) * | 2003-04-25 | 2006-11-02 | ノヴァカーディア,インク. | 腎機能障害を持つ個体における利尿改善法 |
-
2005
- 2005-04-14 KR KR1020067023348A patent/KR20070008689A/ko not_active Application Discontinuation
- 2005-04-14 MX MXPA06011823A patent/MXPA06011823A/es not_active Application Discontinuation
- 2005-04-14 AU AU2005237466A patent/AU2005237466A1/en not_active Abandoned
- 2005-04-14 US US11/107,637 patent/US20050239759A1/en not_active Abandoned
- 2005-04-14 EP EP05735398A patent/EP1755594A1/en not_active Withdrawn
- 2005-04-14 WO PCT/US2005/012724 patent/WO2005105083A1/en active Application Filing
- 2005-04-14 BR BRPI0509753-3A patent/BRPI0509753A/pt not_active IP Right Cessation
- 2005-04-14 JP JP2007508540A patent/JP2007532671A/ja not_active Withdrawn
- 2005-04-14 CA CA002568436A patent/CA2568436A1/en not_active Abandoned
- 2005-04-14 CN CNA2005800123693A patent/CN101094671A/zh active Pending
-
2009
- 2009-06-16 US US12/485,797 patent/US20090253665A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MXPA06011823A (es) | 2006-12-15 |
US20090253665A1 (en) | 2009-10-08 |
WO2005105083A1 (en) | 2005-11-10 |
US20050239759A1 (en) | 2005-10-27 |
EP1755594A1 (en) | 2007-02-28 |
AU2005237466A1 (en) | 2005-11-10 |
KR20070008689A (ko) | 2007-01-17 |
CA2568436A1 (en) | 2005-11-10 |
CN101094671A (zh) | 2007-12-26 |
JP2007532671A (ja) | 2007-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0622054B8 (pt) | composto e composição farmacêutica | |
BRPI0509172A (pt) | pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento | |
CR9808A (es) | Procedimiento de tratamiento de la arterosclerosis, dispilidemias y afecciones relacionadas y composiciones farmaceuticas | |
BRPI0618918B8 (pt) | uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea | |
BRPI0506726B8 (pt) | anticorpo monoclonal específico para m-csf e usos deste | |
BRPI0508931A (pt) | ácido nucleico isolado, composição farmacêutica e usos de uma quantidade eficaz de um primeiro ligante de ácido nucleico | |
BRPI0511139A (pt) | compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente | |
BRPI0515489A (pt) | derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase | |
EA200700118A1 (ru) | Амидосоединения и их применение в качестве лекарственных средств | |
TW200612987A (en) | Combination treatment for non-hematologic malignancies | |
NO20091544L (no) | Sammensetninger av CHK1 inhibitorer | |
CO5670356A2 (es) | Programa de dosificaicon para un nuevo agente anticanceroso | |
NO20055863L (no) | W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer | |
BRPI0510627A (pt) | combinações que compreendem um agonista do receptor s1p e um inibidor da jak3 quinase | |
EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
BRPI0513681A (pt) | composição que compreendem anticorpo her2, método, formulações farmacêuticas, polipeptìdeo, anticorpo e método de tratamento de cáncer | |
BR0316004A (pt) | Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina | |
BRPI0507031A (pt) | composições nematocidas e métodos de uso dessas | |
EP2281561A3 (en) | Use of LCK inhibitors for treatment of immunologic diseases | |
BRPI0509753A (pt) | composição farmacêutica e método de tratamento de doença cardiovascular | |
MY148893A (en) | Combination of an hdac inhibitor and an antimetabolite | |
BRPI0509074A (pt) | composições farmacêuticas compreendendo agonistas do receptor da tiróide | |
EA200701599A1 (ru) | Способ и композиция для восстановления сердечной ткани | |
EP2502996A3 (en) | Anti-FGF23 antibody and pharmaceutical composition comprising the same | |
BRPI0407494A (pt) | composições farmacêuticas e métodos de tratamento de doença cardiovascular, de doença renal, de alcalose ou de nefropatia diabética |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |